Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Thyroidectomy | Research

Comparison of surgical strategies in the treatment of low-risk differentiated thyroid cancer

Authors: András Kiss, Balázs Szili, Bence Bakos, Richárd Ármós, Zsuzsanna Putz, Kristóf Árvai, Barbara Kocsis-Deák, Bálint Tobiás, Bernadett Balla, Henriett Pikó, Magdolna Dank, János Pál Kósa, István Takács, Péter Lakatos

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Context

Increasing diagnostic sensitivity in the detection of thyroid cancer has led to uncertainties in the optimal surgical approach of the smaller, low risk tumors. Current ATA guidelines consider lobectomy safe between 1 and 4 cm, while ETA advocates for primary total thyroidectomy to avoid reoperation, as final risk stratification is based on the histological results.

Objective

Our aim was to compare the differences in outcomes that are potentially achievable with adherence to the different guidelines, and also to examine the predictive value of clinical parameters on the incidence of postoperative risk factors.

Methods

We performed a retrospective cohort database analysis to identify the different surgical outcomes (based on postoperative risk factors) using ATA and ETA guidelines; the hypothetical rate of completion thyroidectomy when ATA or ETA recommends lobectomy; the accuracy of our preoperative evaluation; the utility of preoperative findings in predicting the optimal surgical strategy using binary logistic regression.

Results

Out of 248 patients, 152 (ATA) and 23 (ETA) cases would have been recommended for initial lobectomy. Following the guidelines, a postoperative risk factor would have been present in 61.8, and 65.2% of the cases, respectively. Except for angioinvasion, tumor size was not a significant predictor for the presence of postoperative risk factors.

Conclusion

Current pre-operative criteria are inadequate to accurately determine the extent of initial surgery and our postoperative findings verify the frequent need for completion thyroidectomy using both guidelines. As a consequence, in the absence of effective pre-operative set of criteria, we advocate primary total thyroidectomy in most cases.
Literature
1.
go back to reference Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, Doi SAR. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34(30):3672–9.CrossRef Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, Doi SAR. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34(30):3672–9.CrossRef
2.
go back to reference Kent WDT, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2007;177(11):1357–61.CrossRef Kent WDT, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2007;177(11):1357–61.CrossRef
3.
go back to reference Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-Cancer epidemic? The increasing impact of Overdiagnosis. N Engl J Med. 2016;375(7):614–7.CrossRef Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-Cancer epidemic? The increasing impact of Overdiagnosis. N Engl J Med. 2016;375(7):614–7.CrossRef
4.
go back to reference Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid Cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–48.CrossRef Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid Cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–48.CrossRef
5.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid. Cancer. Thyroid. 2016;26(1):1–133.CrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid. Cancer. Thyroid. 2016;26(1):1–133.CrossRef
6.
go back to reference Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, et al. European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: proceedings of an interactive international symposium. Thyroid. 2019;29(1):7–26.CrossRef Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, et al. European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: proceedings of an interactive international symposium. Thyroid. 2019;29(1):7–26.CrossRef
7.
go back to reference Bozec A, Dassonville O, Chamorey E, Poissonnet G, Sudaka A, Peyrottes I, et al. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Oto-Rhino-Laryngol. 2011;268(8):1205–12.CrossRef Bozec A, Dassonville O, Chamorey E, Poissonnet G, Sudaka A, Peyrottes I, et al. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Oto-Rhino-Laryngol. 2011;268(8):1205–12.CrossRef
8.
go back to reference DiMarco AN, Wong MS, Jayasekara J, Cole-Clark D, Annis A, Glover AR, et al. Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy. BJS Open. 2019;3(3):299–304.CrossRef DiMarco AN, Wong MS, Jayasekara J, Cole-Clark D, Annis A, Glover AR, et al. Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy. BJS Open. 2019;3(3):299–304.CrossRef
9.
go back to reference Duh QY, Shen WT. Clinical implications of postoperative upstaging of differentiated thyroid cancer based upon pathologic evaluation. Endocrine Pract. 2018;24(1):124–5.CrossRef Duh QY, Shen WT. Clinical implications of postoperative upstaging of differentiated thyroid cancer based upon pathologic evaluation. Endocrine Pract. 2018;24(1):124–5.CrossRef
10.
go back to reference Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, et al. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery. 2017;161(1):127–33.CrossRef Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, et al. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery. 2017;161(1):127–33.CrossRef
11.
go back to reference Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European thyroid Cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.CrossRef Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European thyroid Cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.CrossRef
12.
go back to reference Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601–7.CrossRef Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601–7.CrossRef
13.
go back to reference Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33(5):645–9.CrossRef Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33(5):645–9.CrossRef
14.
go back to reference Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2009;34(1):28–35.CrossRef Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2009;34(1):28–35.CrossRef
15.
go back to reference Degroot LJ, Kaplan EL, Mccormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–24.CrossRef Degroot LJ, Kaplan EL, Mccormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–24.CrossRef
16.
go back to reference Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol. 2003;58(4):421–7.CrossRef Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol. 2003;58(4):421–7.CrossRef
17.
go back to reference Robbins RJ, Schlumberger MJ. The evolving role of (131) I for the treatment of differentiated thyroid carcinoma. J Nuclear Med. 2005;46(Suppl 1):28S–37S. Robbins RJ, Schlumberger MJ. The evolving role of (131) I for the treatment of differentiated thyroid carcinoma. J Nuclear Med. 2005;46(Suppl 1):28S–37S.
18.
go back to reference Cha YJ, Koo JS. Next-generation sequencing in thyroid cancer. J Transl Med. 2016;14(1):322.CrossRef Cha YJ, Koo JS. Next-generation sequencing in thyroid cancer. J Transl Med. 2016;14(1):322.CrossRef
19.
go back to reference Dobrescu R, Badiu C. Actualities in genetics of differentiated thyroid cancer. Acta endocrinologica (Bucharest, Romania: 2005). 2020;16(1):118–20.CrossRef Dobrescu R, Badiu C. Actualities in genetics of differentiated thyroid cancer. Acta endocrinologica (Bucharest, Romania: 2005). 2020;16(1):118–20.CrossRef
20.
go back to reference Trimboli P, Scappaticcio L, Treglia G, Guidobaldi L, Bongiovanni M, Giovanella L. Testing for BRAF (V600E) mutation in thyroid nodules with fine-needle aspiration (FNA) read as suspicious for malignancy (Bethesda V, Thy4, TIR4): a systematic review and Meta-analysis. Endocr Pathol. 2020;31(1):57–66.CrossRef Trimboli P, Scappaticcio L, Treglia G, Guidobaldi L, Bongiovanni M, Giovanella L. Testing for BRAF (V600E) mutation in thyroid nodules with fine-needle aspiration (FNA) read as suspicious for malignancy (Bethesda V, Thy4, TIR4): a systematic review and Meta-analysis. Endocr Pathol. 2020;31(1):57–66.CrossRef
21.
go back to reference Xing M. Genetic-guided risk assessment and Management of Thyroid Cancer. Endocrinol Metab Clin N Am. 2019;48(1):109–24.CrossRef Xing M. Genetic-guided risk assessment and Management of Thyroid Cancer. Endocrinol Metab Clin N Am. 2019;48(1):109–24.CrossRef
22.
go back to reference Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(18):2977–82.CrossRef Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(18):2977–82.CrossRef
Metadata
Title
Comparison of surgical strategies in the treatment of low-risk differentiated thyroid cancer
Authors
András Kiss
Balázs Szili
Bence Bakos
Richárd Ármós
Zsuzsanna Putz
Kristóf Árvai
Barbara Kocsis-Deák
Bálint Tobiás
Bernadett Balla
Henriett Pikó
Magdolna Dank
János Pál Kósa
István Takács
Péter Lakatos
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01276-8

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine